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In the post-genomic era, it has become evident that genetic changes alone are not sufficient to understand most
disease processes including pancreatic cancer. Genome sequencing has revealed a complex set of genetic alterations in
pancreatic cancer such as point mutations, chromosomal losses, gene amplifications and telomere shortening that drive
cancerous growth through specific signaling pathways. Proteome-based approaches are important complements to
genomic data and provide crucial information of the target driver molecules and their post-translational modifications.
By applying quantitative mass spectrometry, this is an alternative way to identify biomarkers for early diagnosis and
personalized medicine. We review the current quantitative mass spectrometric technologies and analyses that have
been developed and applied in the last decade in the context of pancreatic cancer. Examples of candidate biomarkers
that have been identified from these pancreas studies include among others, asporin, CD9, CXC chemokine ligand 7,
fibronectin 1, galectin-1, gelsolin, intercellular adhesion molecule 1, insulin-like growth factor binding protein 2,
metalloproteinase inhibitor 1, stromal cell derived factor 4, and transforming growth factor beta-induced protein.
Many of these proteins are involved in various steps in pancreatic tumor progression including cell proliferation, adhesion,
migration, invasion, metastasis, immune response and angiogenesis. These new protein candidates may provide essential
information for the development of protein diagnostics and targeted therapies. We further argue that new strategies must
be advanced and established for the integration of proteomic, transcriptomic and genomic data, in order to enhance
biomarker translation. Large scale studies with meta data processing will pave the way for novel and unexpected
correlations within pancreatic cancer, that will benefit the patient, with targeted treatment.
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Increasing demands in health care today pose high expecta-
tions and directives for the research community to develop
solutions that can improve clinical outcome with improved
cost efficiency. The development of new diagnostic bio-
markers has a great potential and solutions are being tested
both in the pharmaceutical industry and within academic
medicine settings [1-4]. One such area of unmet need is in
the diagnosis and treatment of pancreatic cancer.
Pancreatic cancer is the 10th most common cancer in
the Western world [5]. With an overall 5-year survival rate* Correspondence: roland.andersson@med.lu.se
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unless otherwise stated.less than 5%, it has the lowest survival rate among human
cancers and has become the 4th leading cause of cancer-
related death [6]. An estimated 277,000 new cases of pan-
creatic cancer are diagnosed globally each year with
approximately 266,000 deaths [7]. The total health-care
costs and loss of productivity related to pancreatic cancer
are high, and increasing. In Sweden (population 9.5 mil-
lion), the yearly economic costs for pancreatic cancer was
estimated between EUR 86 and 93 million [8]. Pancreatic
cancer has a low survival as symptoms often are vague and
today there are no established markers for screening, and
early diagnosis. Approximately 85-90% of all patients with
pancreatic cancer are diagnosed with advanced and inop-
erable disease. It has been shown that an improved sur-
vival is achievable when tumors are detected at an earlytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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reported in tumors <2 cm [9] while for tumors <1 cm the
reported 5-year survival rate was found to be close to
100% [10].
For pancreatic cancer, the only biomarker approved by
the FDA and clinically used is carbohydrate antigen 19–9
(CA 19–9). It has been used since the 1980s as a marker
for recurrence and progression, based on a study where
CA 19-9 outperformed carcinogenic antigen (CEA) in pre-
dicting recurrence following surgery [11]. It has been
found that CA 19–9 has a relatively high sensitivity and spe-
cificity (about 80% as seen in 22 studies) [12] which is super-
ior to other markers, including CEA, CA-50 and DUPAN-2
[12-14]. However, the low positive predictive value taken
together with the fact that benign causes and all forms of
biliary obstruction, can trigger an increase in CA 19–9
serum levels, diminish its utility as a screening tool [12,15].
Additionally, 10% of the population do not have the enzyme
activity genotype (le/le) and consequently cannot synthesize
CA 19–9 [16]. Despite this, CA 19–9 is considered the best
serum marker for pancreatic cancer and the one against
which new markers should be judged [17].
Systems biology and one of its supporting disciplines,
proteomics, has evolved widely over the past decade, pro-
viding novel methods to tackle increasing challenges in
health care. With increasing knowledge and improved
techniques, the field of proteomics has introduced a new
paradigm for detecting disease at an early curable stage.
Proteomics is no longer a protein expression methodology
for specialists. On the contrary, proteomics is used and ap-
plied to all areas of life science today. Proteomics is espe-
cially applicable in the treatment of pancreatic cancer,
where successful treatment is directly related to early inter-
vention [18]. Today the accuracy, sensitivity and specificity
of proteomics is directly linked to the development of high
performance mass spectrometry instruments for the meas-
urement of analytes in clinical samples. Modern high-end
mass spectrometry platforms enable high-resolution power
in sequencing, as well as identifying post-translational-
modifications [19]. Mass spectrometry also offers a way to
localize new disease regulating proteins for target-specific
anti-cancer drugs, renewing a hope for a breakthrough in
the treatment outcome of pancreatic cancer, like the one
seen in other malignancies, with personalized medicines
such as Imatinib in Philadelphia chromosome-positive
acute myeloid leukemia (Ph+AML) [20] and Gefitinib
(IRESSA), as well as Tarceva (Erlotinib) in the therapy of
non-small cell lung cancer [2].
The basic concept that health and disease differ in
gene and protein regulatory networks is well established.
Genome sequencing has revealed a complex set of genetic
alterations in pancreatic cancer such as point mutations,
chromosomal losses, gene amplifications and telomere
shortening that drive cancerous growth through specificsignaling pathways [21,22]. Functional studies are needed
in order to investigate which pathways that are critical on
a protein level. Today’s mass spectrometry instrumenta-
tion and its merits were pioneered by Fenn’s group on
electrospray ionization [23], while Karas and Hillenkamp
[24] and Tanaka [25] developed Matrix Assisted Laser De-
sorption Ionization – “MALDI” mass spectrometry. These
were milestone inventions that revolutionized modern
Post-Genomic research, and were awarded the Nobel
Prize in 2002. These inventions have further changed our
way of working with clinical protein science today.
Increasing our understanding of the biological drivers of
pancreatic cancer could serve to identify new diagnostic
and therapeutic biomarkers. Here, we give an overview on
the role of quantitative mass spectrometry in the discov-
ery, validation and translation of new biomarkers for pan-
creatic cancer patients. We argue for a global, integrated
proteomic and transcriptomic work flow in the analysis of
pancreatic tumors. The establishment of custom databases
and comparison with genomic data such as ENCODE, is
mandatory in order to discover and utilize new molecular
entities within disease mechanisms.
The biomarker concept
The biomarker concept is not a new invention per se.
Its utilization has been exploited in both medicine, as
well as within the drug development process. However,
a distinction should be made to the surrogate marker,
that is a definite indicator of a medical, or pathophysio-
logical event. The National Institutes of Health (NIH)
Biomarker working group defined a biomarker as “a
characteristic that is objectively measured and evalu-
ated as an indicator of normal biologic processes,
pathogenic processes, or pharmacologic response to a
therapeutic intervention [26].”
Biomarkers can be further divided with respect to their
utility in care [27]:
Diagnostic biomarkers: Detect onset, recurrence after
surgery, supplying therapy guidance, or identifying
progression of disease.
Prognostic biomarkers: State the natural disease process
and can assist in treatment planning. Give insight about
survival and recurrence patterns.
Predictive biomarkers: Predict the response to treatment.
Considering the disposition in clinical studies, biomarkers
can be divided into several classes [2]:
1. Primary biomarkers (low abundant), such as receptor
signaling kinases.
2. Secondary biomarkers (low/medium abundant),
indirect biomarkers that are a resulting outcome of
the signaling pathway biology.
Ansari et al. Journal of Translational Medicine 2014, 12:87 Page 3 of 15
http://www.translational-medicine.com/content/12/1/873. Tertiary biomarkers (medium/high abundant), are
proteins that are associated with functional changes
in disease.
4. Disease biomarkers (can be low/medium/high
abundant).
Proteomic profiling in the search for pancreatic cancer
biomarkers is usually based on tissue, pancreatic juice (the
secretions of the exocrine portion of the pancreas), and/or
blood (serum or plasma).
As there are a number of disease mechanisms involved
in pancreatic cancer, we are not at a stage where we have
a disease-linked targeted route that provides efficacious
outcomes. That is a challenge in itself. This is one of the
salient reasons for using tissue samples that represent
large disease regions in the pancreas in the hunt for dis-
ease related biomarkers. As such, by studying the tissue
compartment where the disease occurs, we gain in the
understanding of the origin and the basis of disease
mechanisms, and protein drivers involved in that origin,
as well as progression of disease. Once we have built an
understanding of the changes in protein expression in the
diseased tissue, we are facilitated to test for similar
markers in other body fluids such as blood. When
analyzing tissue in proteomic studies, formalin-fixed, par-
affin-embedded (FFPE) tissue is more accessible than
snap-frozen tissue specimens. FFPE tissue specimens are
clinically and pathologically well defined, which allow a
direct correlation of histological observations with prote-
omic analysis [28,29]. Recent developments in methodolo-
gies of protein extraction techniques from FFPE samples
provide new opportunities for larger sets of study mate-
rials to be used in the survey of protein expression. The
utility of laser microdissection along with FFPE, followed
by proteomic studies, may allow the isolation of cancer
cells and stromal cells to accurately determine the prote-
ome profile of different tumor compartments [30,31].
Pancreatic juice is a biofluid which is in contact with pro-
teins directly secreted from the pancreatic ducts. The possi-
bility of shed cancer cells, makes the juice a rich biomarker
source, and an opportunity due to the cancer-specific pro-
teins expressed in these samples.
The human plasma proteome is the most accessible bio-
fluid, and has the potential to significantly improve disease
diagnosis and therapeutic monitoring [32]. However, given
the low abundance in serum and plasma of known cancer
biomarkers [33], new proteomic technologies are con-
stantly being developed and refined to provide sufficient
depth of analysis for biomarker quantification.
Modern high-end mass spectrometry
Traditionally, two-dimensional gel electrophoresis (2-DE),
resolving the proteome at a protein level, has in the past
been extensively used in proteomic studies. The methodutilizes the net charge of proteins at different pH values
(isoelectric focusing) and the molecular weight of proteins
to separate them in a two-dimensional pattern in the gel
medium. The protein “spots” generated can then be
stained (fluorescent tags), and consequently analyzed with
different methods to identify and quantify the specific pro-
teins. 2-DE was first introduced in 1975 by O’Farell [34]
and gel electrophoresis has since experienced great im-
provements also within the context of pancreatic cancer
[35,36]. However, it still carries limitations in gel reprodu-
cibility, and has a poor representation of highly basic/
acidic, low abundant proteins and membrane proteins. A
major limitation with 2-DE, is the inherent difficulty, to
identify the proteins by MS-sequencing, as there is a limi-
tation in excising proteins from the polymeric matrix of
the gels. In addition, the low accuracy when comparing
multiple proteins and difficulties in automation render this
method unreliable and it may need to stand aside for the
new gel-free mass spectrometric techniques [37]. In clin-
ical protein science, new and future complementary tech-
nologies, like quantitative mass spectrometry including
protein shotgun sequencing has been instrumental in
these achievements [38-40]. One approach that has gain
most acceptance over the last decade is liquid phase separ-
ation interfaced on-line with mass spectrometry [2,41,42].
It can be used for the identification and quantification of
proteins across multiple sample sets. It can be used for
protein deep mining studies (biomarker discovery) and
targeted protein quantification (biomarker validation). It
can also be used to detect post-translational modifications
(PTMs).
Protein deep mining
Protein deep mining studies can be performed using either
label-free or labeled mass spectrometric approaches. These
approaches have recently gained interest in the context of
pancreatic cancer. Examples of candidate proteins have
been identified. All of these biomarker candidates have been
validated in tissue or biofluids (pancreatic juice, serum or
plasma) of pancreatic cancer patients (as shown in Table 1).
Label-free quantification
Label-free quantification is based on the signal intensity
created by the peptides in the mass spectrometer. The
quantification is often performed using peak-intensity
[43,44] or spectral counting [45-47]. These are straight-
forward techniques compared to labeled procedures.
First, the individual samples are processed and analyzed
by LC-MS. The LC separation step is used to reduce the
complexity of analytes in the sample. Over 20,000 circu-
lating peptides have been identified in human plasma
[48]. Normalization is required to minimize the affec-
tion of slightly different constitutions of samples. Sev-
eral peptides per protein should be quantified to certify
Table 1 Protein deep mining studies in pancreatic cancer using mass spectrometry
Technique Sample type Groups Discovery phase Biomarker candidates References
Label-free Tissue PC, N 1,009 proteins in total; 422 upregulated proteins in PC ASPN, LTBP2, TGFBI Turtoi et al. [49]
Tissue PC, N 1,229 proteins in total; 499 upregulated in PC ECH1, GLUT1 (GTR1), OLFM4, STML2 Takadate et al. [30]
Tissue PC, CP, N 525 proteins in total; 21 upregulated proteins in PC ANXA4, FN1 Paulo et al. [65]
Plasma PC, N 53,009 MS peaks CXCL7 Matsubara et al. [69]
SILAC Cell lines PC, N 195 proteins in total; 68 upregulated proteins in PC;
5 biomarker candidates validated in pancreatic cancer tissue
CD9, HSPG2, APOE, SDF4, ITGB1 Grønborg et al. [81]
Serum PC, N 1,065 proteins in total; 121 upregulated proteins in PC BCAM, ICAM1 Yu et al. [ 94]
ICAT Tissue PC, N 656 proteins in total; 151 upregulated proteins in PC ANXA2, ITGB1 Chen et al. [100]
Pancreatic juice PC, N 105 proteins in total; 30 upregulated proteins in PC IGFBP2 Chen et al. [103]
Acrylamide- labeling Plasma PC, CP, N 1,340 proteins in total; 95 and 87 proteins with ≥1.5 fold
difference in PC compared to N and CP, respectively
ICAM1, TIMP1 Pan et al. [106]
TMT Serum PC, N 752 proteins in total APOA4, F12, GSN, LTF Sinclair et al. [110]
ICAT, iTRAQ Tissue PanIN-3, PC, CP, N 770 proteins in total; 70 proteins upregulated and 133
downregulated in PanIN-3
ACTN4, LAMB1, LGALS1 Pan et al. [119]
ACTN4, actinin alpha-4; ANXA2, annexin A2; ANXA4, annexin A4; APOE, apolipoprotein E; APOA4, apolipoprotein A-IV; ASPN, asporin; BCAM, basal cell adhesion molecule; CP, chronic pancreatitis; CXCL7, CXC chemokine
ligand 7; ECH1, enoyl CoA hydratase 1; F12, coagulation factor XII; FN1, fibronectin 1; GLUT1 (GTR1), glucose transporter member 1; GSN, gelsolin; HSPG2, heparan sulfate proteoglycan 2 (perlecan); ICAM1, intercellular
adhesion molecule 1; IGFB2, insulin-like growth factor-binding protein 2; ITGB1, integrin beta-1; LAMB1, laminin beta-1; LGALS1, galectin-1; LTBP2, latent transforming growth factor beta binding 2; LTF, lactotransferrin;
N, normal; OLFM4, olfactomedin-4; PanIN-3, pancreatic intraepithelial neoplasia; PC, pancreatic cancer; SDF4, stromal cell derived factor 4; STML2, stomatin-like protein 2; TGFBI, transforming growth factor
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there is a need for high-resolution multidimensional chro-
matography. The orthogonal approach is crucial in order
to utilize additive parts within the protein structure that
aids in the chromatographic separation mechanisms [2].
Recently in a study, Turtoi et al. [49] used label-free
quantification of pancreatic cancer and normal pancreas
tissues to identify systemically accessible proteins, defined
as proteins located on the outer surface of the cell mem-
brane and/or in the extracellular matrix, having the poten-
tial to serve as targets for diagnostic and therapeutic
approaches. Eleven selected candidates were further con-
firmed as up-regulated by western blot, and multiple reac-
tion monitoring (MRM) protein quantification. Of these,
transforming growth factor beta-induced (TGFBI), latent
transforming growth factor beta binding 2 (LTBP2), and
asporin (ASPN) were further investigated by immunohis-
tochemistry and found to be overexpressed in a large col-
lection of pancreatic cancer tissues compared to normal
and inflammatory tissues. These candidates had not previ-
ously been linked to pancreatic cancer at the level of pro-
tein expression. TGFBI is a secreted extracellular matrix
protein that is overexpressed by several cancer types, and
is suggested to promote metastatic progression [50-53].
TGFBI may induce dissociation of VE-cadherin junctions,
and eventual breakdown of the endothelial barrier via the
integrin alpha-v beta-5 and the Src signal pathway, leading
to increased cancer cell extravasation [52]. The other can-
didate protein, LTBP2, is reported to have a role in cell ad-
hesion, and TGF-beta1 increases expression of LTBP2 at
the transcriptional level [54,55]. ASPN is a member of the
small leucine-rich proteoglycan (SLRP) family. Little is
known regarding the function of ASPN in pancreatic can-
cer, but it is supposed to have a role in TGF-beta/Smad
signaling [56].
In another deep mining proteomics study, Takadate
et al. [30] used label-free quantification of pancreatic
cancer tissues with poor and better survival outcomes, and
non-cancancerous pancreatic ducts. Of these proteins, 170
were selected for MRM protein quantification. Of these,
fourteen proteins were found to be overexpressed in pan-
creatic cancer compared to normal tissue. Furthermore,
patients whose tumors expressed the proteins enoyl-CoA
hydratase 1 (ECH1), olfactomedin-4 (OLFM4), stomatin-
like protein 2 (STML2) and glucose transporter member 1
(GLUT1 or GTR2) had significantly worse survival, sug-
gesting that these proteins may have prognostic value, and
may serve as new therapeutic targets. ECH1 is an enzyme
that functions in the auxiliary step of the fatty acid beta-
oxidation pathway. Upregulation of ECH1 is associated
with cancer cell proliferation, increased ratio of cells in S
phase to G1 phase, and increased migration capacities, and
may have an important role in the development of lymph-
atic metastasis [57]. OLFM4 is an extracellular matrixglycoprotein that regulates cell adhesion and is also
considered to be an antiapoptotic factor that promotes
tumor growth [58]. STML2 is a member of the stomatin
superfamily. It has been identified as an oncogenic-
related protein and found to be overexpressed in several
cancers [59-61]. STML2 down-regulation can inhibit
cancer cell invasion in an MMP2 dependent manner
[60]. Also, the up-regulation of STML2 is involved in
activation of the MAPK/ERK pathway [60]. GLUT1 is a
member of the facilitative glucose transporter family.
The GLUT1 protein is considered to be upregulated
in tumor cells, which have enhanced metabolism and
increased glucose requirements [62]. An increased
GLUT1 expression has also been linked to pancreatic
cancer invasiveness and poor prognosis [63,64].
Another study by Paulo et al. [65] used label-free quanti-
fication of pancreatic cancer, chronic pancreatitis and nor-
mal pancreas tissues. Of these proteins, 21 proteins were
identified exclusively in pancreatic cancer specimens in-
cluding annexin 4A (ANXA4) and fibronectin (FN1).
ANXA4 is a member of the annexin family of calcium-
dependent phospholipid binding proteins. ANXA4 is sug-
gested to be implicated in proliferation, migration and
chemoresistance of cancer cells [66,67]. The other candi-
date, FN1, is a glycoprotein involved in cell adhesion and
migration processes. The presence of both cellular and
stromal FN1 and its interaction with integrins is necessary
for pancreatic cancer progression, and inhibition of FN1
signaling was previously shown be an effective treatment
strategy in vivo [68].
Matsubara et al. [69] used label-free quantification of
plasma from pancreatic cancer patients and healthy con-
trols. Of the MS peaks, a peptide derived from CXC che-
mokine ligand 7 (CXCL7) was significantly reduced in
pancreatic cancer patients. Reduction of the CXCL7 pro-
tein in pancreatic cancer was also observed in a validation
cohort. Interestingly they found that the combination of
CA 19–9 with CXCL7 significantly improved the AUC
value of CA19-9 to 0.961. CXCL7 belongs to the CXC che-
mokine family and is a proangiogenic and proinflamma-
tory cytokine. The reduction of circulating CXCL7 in
patients with pancreatic cancer may have a role in the sup-
pression of angiogenesis, and may reflect the hypoxic nature
of pancreatic cancer tissue [69]. Plasma CXCL7 may be de-
graded by exoproteases such as matrix metalloproteinase-9
(MMP9) that are secreted into the plasma by pancreatic
cancer cells [70-72].
Labeled quantification
The labeling of proteins and peptides with stable heavy
isotopes (deuterium, carbon-13, nitrogen-15, and oxygen-
18) have been used in clinical and pharmacologic settings
for decades, but have recently found a major part explor-
ing the possibilities promised by contemporary proteome
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chemical or enzymatic reaction, can be used to incorpor-
ate the labeling isotopes. After fragmentation, peptides or
reporter ions are used for quantification of the targeted
proteins based on their signal intensities in mass spectro-
metric analysis [73]. The incorporation of isotope-labeling,
makes the labeled peptides become the internal standard
of the assay. This procedure provides a unique feature, to
identify endogenous analytes in the sample, where even
highly complex samples can be screened by this method-
ology [74]. The advantage of utilizing isotope labeled in-
ternal standards is also that these protein sequences do
not exist naturally in human samples. The methods based
on residue-specific chemical derivatization with labeled re-
agents offers great flexibility are universally applicable, but
may sometimes become too complicated, resulting in un-
wanted side reactions. The metabolic approaches do not
require any manipulation of the proteins but are limited
to cells where full control of culturing can be obtained
[75]. The quantitative analysis can be “isotopic” or “iso-
baric” with the main difference that isotopic methods
(SILAC. ICAT, and ICPL) quantify peptides at the MS
level based on ion intensities of light and heavy isotopes of
a peptide. While the isobaric methods (TMT, and iTRAQ)
quantify peptides at MS/MS level, based on comparison of
measured reporter ion intensities [76].
Metabolic labeling
Stable isotope labeling by amino acids in cell culture
(SILAC) is a metabolic isotope-labeling technique incorp-
orating specific amino acids in vivo into mammalian pro-
teins [77-79]. The cell lines are grown in a media where a
standard essential amino acid is exchanged by a non-
radioactive, isotopically labeled form and thus incorpo-
rated into all proteins synthesized. This step has been
shown to not influence the growth of the cells. It takes a
certain number of cell doublings for the complete incorp-
oration of the isotopically labeled analog into the proteins
studied. Proteins from the experimental and control sam-
ples are mixed and mass spectrometric measurements are
used for relative quantification. It is a simple, inexpensive
and accurate technique applicable to any cell culture sys-
tem. Chemical labeling and affinity purification steps are
not involved in this process, but the downside is that it re-
quires living cells. However, Geiger et al. [80] recently de-
veloped a method called Super-SILAC for quantitative
proteomics on human tumor tissue.
Grønborg et al. [81] was one of the first research teams
to provide protein expression database annotations, using
SILAC, to compare the secretomes of the human pancre-
atic cancer cell line PANC1 and the normal pancreas cell
line HPDE. Eleven dysregulated proteins were verified by
western blot analysis. Five proteins including CD9, perlecan
(HSPG2), apolipoprotein E (APOE), stromal cell derivedfactor 4 (SDF4), and fibronectin receptor/integrin β1
(ITGB1) were subsequently validated by immunohisto-
chemistry on human pancreatic cancer tissue. CD9 is a cell
surface glycoprotein that belongs to the tetraspanin family.
It is involved in many cellular processes including cell adhe-
sion, and signal transduction, and also plays a critical role
in the suppression of cancer cell motility and metastasis
[82]. Low CD9 expression is related to poor prognosis in
several cancers including pancreatic cancer [82,83]. HSPG2
is a pericellular proteoglycan that controls cell migration,
proliferation, and differentiation [84]. HSPG2 can interact
with growth factors and facilitate cancer growth and angio-
genesis [84,85]. APOE is a ligand for low density lipoprotein
receptors [86]. Besides its role in cholesterol transport and
metabolism, APOE is also involved in several diesease pro-
cesses. APOE can affect cell growth, proliferation, and im-
mune response [87,88]. APOE is elevated in several
malignancies including pancreatic cancer [89,90]. It has
been suggested tumor promoting effects of APOE is may
be related to the inhibition of TNF-alpha [91]. SDFs refer
to a group of proteins that are generated by stromal cells.
While it has been shown that SDF1 is overexpressed in ag-
gressive pancreatic tumors and high levels of SDF1 are
linked to a poor prognosis [92], the significance of SDF4 is
in pancreatic cancer is less known. ITGB1 is a membrane
receptor in the integrin family, and is involved in cell adhe-
sion and can facilitate metastatic spread of cancer cells
through interactions with the extracellular matrix [93].
In an additional recent study, Yu et al. [94] used SILAC
to collect secreted proteins from the human pancreatic
cancer cell line CAPAN-2. The resulting stable isotope la-
beled proteome (SILAP) standard was added to each
pooled sample from pancreatic cancer and benign pancre-
atic disease. Proteins were separated by isoelectric focusing
before 2D-LC-MS/MS analysis. Independent validation
was performed with ELISA for two proteins, intercellular
adhesion molecule 1 (ICAM1) and basal cell adhesion
molecule (BCAM). ICAM1 has a role in cell–cell and cell–
extracellular matrix adhesion. ICAM1 has previously been
reported to be overexpressed in pancreatic cancer, and
serves as an important docking point for polymorpho-
nuclear cells that functionally promote tumor cell metasta-
sis [95,96]. BCAM is a laminin receptor and a member of
the immunoglobulin superfamily. Little is known about the
role of BCAM in pancreatic cancer, but laminin alpha 5 is
widely expressed in basement membranes, and therefore it
has been suggested that BCAM may play a role during the
process of tumor invasion [97].
Isotopic labeling
Isotope-coded affinity tags (ICATs) is a class of reagent,
consisting of three functional elements; a chemical group
reactive towards cysteines (thiol groups), an isotopically
coded linker, and an affinity tag (biotin) used in the
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technique used on either cells or tissue for relative quantifi-
cation because it is based on stable isotope dilution. One
heavy (deuterium) and one light (hydrogen) form exist for
every reagent. The two samples being compared are intro-
duced to the ICAT reagents that covalently attached to
each cysteinyl residue in every protein. One sample receives
the light and the other receives the heavy form. The two
samples are then combined and reacted with proteolytic
enzymes to produce peptide fragments. The ICAT-labeled
(cysteine-containing) peptides with their biotin tag can then
be isolated by an avidin affinity chromatography. The iso-
lated peptides are then separated and analyzed by a liquid
chromatography-MS/MS procedure. An automated multi-
stage MS generates both the quantity and sequence identity
of the originally tagged proteins. The ratio of signal inten-
sities of peptide pairs between the samples (differing with 8
Dalton mass) utilized with MS provides an accurate meas-
ure of the relative quantities. It is thus important to have
the same ratios of the original amounts of proteins from
the two samples through the whole process [98]. Improve-
ments have been made using other isotopes than deuter-
ium. Most recently an approach using Carbon-13 as the
heavy element resulted in an increase of the number of pro-
teins identified per experiment. The retention time shift, a
common problem with labeled techniques caused by sig-
nificantly altered hydrogen bonding of deuterated com-
pounds, could also be avoided with this approach [99].
In a recent study, Chen et al. [100] used ICAT applied to
pancreatic cancer tissues and matching normal pancreas
samples. Annexin A2 (ANXA2) was identified as a bio-
marker for pancreatic cancer. ANXA2 is part of the
annexin family of proteins. It has been shown that ANXA2
can mediate epithelial to mesenchymal transition, invasion,
and metastases in pancreatic cancer, for example through
translocation from the cytosol to the cell membrane
[101,102]. Chen et al. [100] validated ANXA2 and the other
discovered protein, ITGB1, using western blotting, and
immunohistochemistry.
In another study, Chen et al. [103] used ICAT of pancre-
atic juice from a pancreatic cancer patient and normal con-
trols. One of the identified proteins, insulin-like growth
factor binding protein-2 (IGFBP2), was further validated by
western blotting to be elevated in pancreatic cancer juice
and overexpressed in pancreatic cancer tissue. IGFBP2 has
been found to be overexpressed in many malignant tissues,
including pancreatic cancer [35,104,105]. Insulin-like
growth factors (IGFs) and IGF binding proteins (IGFBPs)
are responsible for growth of neoplastic cells through auto-
crine and paracrine mitogenic signals [104].
Complementary to these studies, Pan et al. [106] used
stable isotopic heavy and light acrylamide labels of plasma
from pancreatic cancer patients, chronic pancreatitis pa-
tients and non-pancreatic disease controls. They foundthat metallopeptidase inhibitor 1 (TIMP1), a natural tis-
sue inhibitor of matrix metalloproteinases (MMPs)
which degrade extracellular matrix, was identified as a
biomarker candidate for pancreatic cancer. TIMP1 has
been previously shown to reduce pancreatic cancer cell
growth, metastasis, and angiogenesis, while increasing
tumor apoptosis [107]. Pan et al. [106] found that TIMP1
together with ICAM1 demonstrated a significantly better
performance than CA19-9 in distinguishing pancreatic
cancer from the controls.Isobaric labels
Tandem mass tags (TMTs) is a MS/MS-based strategy
using isotopomer isobaric labels for accurate quantification
of peptides and proteins. The tags are comprised of differ-
ent regions. The sensitization and mass differentiation
group are cleaved during collision-induced dissociation
(CID) and constitutes the TMT fragment being detected
and used for quantification. Unlike other methods the pairs
of TMT-tagged peptides have the same overall mass due to
a mass-normalization group, and thus co-migrate in chro-
matographic separations leading to a more precise quanti-
fication. The co-migration means that the MS signal peak
for each peptide pair will not be split, improving sensitivity
in MS mode. The reactive functionality of the tags can be
manipulated, so that it allows a coupling and labeling of
any peptide to be made. The second generation tag differ
from the first by introducing an additional fragmentation-
enhancing group [108]. The TMT labeling allows for sim-
ultaneous identification and relative quantification, on MS/
MS fragmentation. Improved 6-plex TMTs have been de-
signed to be able to compare up to six different extracts. It
uses 13C or 15 N instead of H in the former 2-plex TMTs
that guaranties co-elution during the LC separation [109].
An elegant example was recently presented by Sinclair
et al. [110] who showed that they could use amino-group
labelling of proteins with TMT of sera from pre-diagnosis
pancreatic cancer cases, and matched healthy controls sam-
ples. Examples of consistent protein expression changes all
the way up to clinical diagnosis of pancreatic cancer, were;
gelsolin (GSN), apolipoprotein A4 (APOA4), coagulation
factor 12 (F12) and lactotransferrin (LTF). GSN is an actin-
capping protein and GSN levels are actively downregulated
in pancreatic cancer and the ubiquitin-proteasome pathway
is an important contributing factor for this effect [111].
APOA4 levels are also significantly decreased in patients
with pancreatic cancer [112]. F12 may facilitate cancer cell
metastasis by transforming monocytes-macrophages to-
ward tumor-associated macrophage-like cells [113]. LTF
plays important role in innate immunity, and it has been
shown that LTF is significantly down-regulated in pancre-
atic cancer [114]. LTF may act as a tumor suppressor by
suppressing AKT signaling [115].
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(iTRAQ) is based on covalent labeling of the N-termini
and lysine side chains. It contains one reporter group, an
amine-reactive group, and a balancing group between
them. It can either be 4-plex or 8-plex, both isobaric
with a mass of 145 to 305 Da, respectively. The balancer
group is not detectable by MS because it is liberated as a
neutral fragment within the assay. The reporter group is
cleaved during CID generating quantifiable isotope frag-
ments. The quantification is exclusively done on MS/MS
level, reducing chemical noise and improving precision
compared to MS-based techniques [116]. With iTRAQ,
up to eight relative quantifications can simultaneous be
done in a single run. A disadvantage with isobaric labels
is that there may be interference due to overlapping pre-
cursor ions. Several approaches have been conducted to
overcome this limitation, such as using an additional
step with isolation and fragmentation [117,118].
Pan et al. [119] used iTRAQ and ICAT of immediate
precursor of pancreatic cancer (PanIN 3), pancreatic can-
cer, chronic pancreatitis and normal pancreas tissues. Net-
work analysis of the proteins identified c-MYC as an
important regulatory protein in PanIN 3 lesions. Further-
more, three of the overexpressed proteins, laminin beta-1
(LAMB1), galectin-1 (LGALS1), and actinin-4 (ACTN4)
were validated by immunohistochemistry analysis. All
three of these proteins were overexpressed in the stroma
or ductal epithelial cells of advanced PanIN lesions as well
as in pancreatic cancer tissue. LAMB1 belongs to a group
of basement membrane proteins that significantly enhance
the invasive behavior of pancreatic cancer cells [120].
GAL1 is a beta-galactoside-binding lectin that can induce
chemokine production and proliferation in pancreatic stel-
late cells which promote pancreatic fibrosis and tumor
progression [121,122]. Actinin-4 is an actin-binding protein
associated with enhanced cell motility, invasive growth,
and poor survival in pancreatic cancer [123,124]. E-
cadherin regulates the association between beta-catenin
and actinin-4 [125].Targeted protein quantification
Following discovery-based deep mining studies, several
biomarker candidates need to be selected for further
studies, based on phenotype specificity and/or direct
mechanistic role in the disease. Using more targeted
protein analyses such as selected reaction monitoring
(SRM; or MRM plural), these biomarkers can then be
validated in large patient cohorts (see Figure 1). Tar-
geted protein analyses allow simultaneous quantitation
and identity confirmation with high sensitivity in a sin-
gle LC-MS/MS run. By utilizing isotop labeled internal
standards, the absolute abundances of each protein can
be determined.MRM assay principles
Targeted analysis of single or multiple proteins (multiplex)
using LC-MS technology in MRM mode, has gained exten-
sive attention recently. MRM is a mass spectrometric scan
type with the highest duty cycle that can monitor one or
more specific ion transition(s) at high sensitivity. MRM as-
says are becoming a true complement to ELISA assays. It
has already been shown that an MRM assay is capable of
monitoring 50 proteins simultaneously [126]. In order to
push sensitivity of low abundant proteins in terms of tech-
nology a sample preparation step is needed. To be able to
compete with the sensitivity of ELISA, which is capable of
quantifying proteins at low picogram per milliliter levels,
immunoaffinity-assisted LC-MS/MS analysis has emerged.
Recent developments in immunoaffinity-assisted LC-MS/
MS analysis have been able to show picogram per milliliter
sensitivities [127,128]. MRM is a more cost-effective and
timesaving assay than standard ELISA assays and has the
capacity to quantify multiple proteins in one analysis with
high reproducibility.
The development of MRM assays is based on the selec-
tion of one or several target peptides for each protein
within the assay. The samples are digested, commonly with
trypsin, followed by LC-MS. Chemically stable isotope-
labeled peptides are most commonly used for MS-based
absolute quantification of proteins in the multiplex MRM
assay developments.
In Silico processing
When developing an MRM assay, the first step is the in
silico processing. In silico methodology is used specifically
in the selection process, to build the multiplex protein
assay [129,130]. The selection of a unique peptide repre-
sentative for the targeted protein or a specific isoform
thereof is a critical step to generate true and replicable re-
sults. These peptides are termed proteotypic peptides
(PTPs) and from these the fragment ions generating opti-
mal signal intensity and discriminate the targeted peptide
have to be identified. To obtain the most reliable selection,
the fragment ion masses of the targeted peptide can be
calculated and experimentally tested by SRM measure-
ments on a triple quadrupole instrument. For time-saving
and help in the selection of target peptide set information
can be gathered from previous experiments or from the
emerging online databases (including PRIDE, PeptideAtlas
and Human Proteinpedia) [131].
To get a more reliable quantification, at least two pep-
tides should be monitored for each targeted protein where
any divergence in regulation can be assumed to stem from
post-translational modifications and/or overlapping protein
sequences [131]. Studies have evaluated the application
of MRM in determining post-translational modifications.
The technique MRM-initiated detection and sequencing
(MIDAS) has been shown to be highly sensitive in







Figure 1 Protein assay development in pancreatic cancer from discovery to validation.
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acetylation [132,133].
The complexity of mammalian systems makes it possible
for multiple proteins to act as precursors of a single peptide
and thus result in under- or overestimation of the discov-
ered marker candidates [134]. Peptides containing side
chains from methionine or tryptophan residues are prone
to oxidation, while peptides containing glutamine or as-
paragine residues may convert to glutamate or aspartate.
Caution should be raised towards peptides, observed in
shotgun analyses, with missed cleavages or non-tryptic
cleavage sites. Two neighboring basic amino acids at either
cleavage site are prone to high rate of missed cleavages. It is
important to have a unique set of transitions; otherwise
precursor/fragment ion pairs with similar masses can create
unspecific signals. A high abundant protein or one generat-
ing a strong signal might thus disturb the signal from the
protein being studied [131].Several systems exist to support the procedure. They
can help in the selection of targeted protein sets, finding
representative PTPs, and manage and validation of transi-
tions to get more reliable data. The dedicated analysis soft-
ware “Skyline”, supports the direct picking of peptide,
precursor and transition in silico from proteins and frag-
ment peptides [135]. Other platform-specific tools include
TIQAM, MRMPilot, SRM Workflow Software, Verify, and
Optimizer [131]. MRMer is another open source software
tool, for the analysis of data generated by highly complex
MRM-MS experiments. It provides a rapid visual inspec-
tion of over 1000 precursor-product pairs [136].
The highest sensitivity of MRM-MS requires optimal
peptide fragmentation and maximal transmissions of the
desired product ions, which is dependent on optimal set-
tings of parameters that includes collision energy, cone
voltage, and de-clustering potential. Methods for fine-
tuning the parameters have been developed [137].
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interfering signals or inconsistent recovery among replicate
samples are being developed to reduce the need for manual
and subjective inspection of data, and thus improve the
overall accuracy and minimize errors [138].The MRM technology platform of biomarkers
The primary benefits of MRM assays are their multiplexing
capabilities. This allows panels of proteins to be quantitated
in a single assay cycle. In principle, any protein can become
an analyte. Although antibody-based techniques, such as
ELISA, represent the current gold standard for protein bio-
marker quantification, the development of high quality
antibody assays requires time and resources and has been a
limitation in biomarker translation. The multiplexing cap-
abilities and the generic concept of the MRM assay makes
it superior to current ELISA assays [139]. In recent years,
several studies have demonstrated the value of using tar-
geted MRM proteomics for candidate pancreatic cancer
biomarker validation.
The studies by Tortoi et al. [49] and Takadate et al.
[30] used protein deep mining followed by MRM ana-
lysis as described in the previous section.
Pan et al. [85] applied an MRM-based targeted proteo-
mics platform to directly detect candidate biomarker
proteins in plasma. The study included patients with pan-
creatic cancer and chronic pancreatitis, as well as healthy
individuals. Plasma was first depleted to remove albumin
and IgG. Three of the 5 candidate proteins, including
GSN, lumican (LUM; a member of the SLRP family), andFigure 2 Workflow for biomarker translation in pancreatic cancer usinTIMP1, demonstrated an AUC value above 0.75 in differ-
entiating pancreatic cancer from the controls.
Yoneyama et al. [140] used MRM quantification of
proline hydroxylation at residues 530 and 565 of alpha-
fibrinogen. The results indicate that PTMs can be used
as biomarkers of pancreatic cancer, and also identify
CA19-9-negative patients.Large meta-data studies
Large scale studies with meta data processing is a new de-
velopment area, where the analysis of archived biobank
samples is and will play a major role is within the field of
new biomarkers and new diagnostic developments. It can
be seen that both industry as well as the academic field in-
vest and are adding large resources, searching for ap-
proaches to improve on the discovery successes where
new technology plays a central role. Here, the ENCODE
initiative has over the years produced an extensive DNA-
sequence resource that is being utilized by the Proteomics
Community [141]. The human genome sequencing plat-
forms including the latest generation of deep-sequencing
platforms, allows us to integrate new data with genetic risk
factors, aligning with proteomics data [19,142].
To get a comprehensive understanding of protein
changes in disease will require quantitative information
from proteomic, transcriptomic and genomic data. Re-
cently, whole transcriptome analysis using RNA sequen-
cing revealed an average of 109 million mapped reads in
pancreatic cancer and 877 genes and isoforms identified
as showing significant expression changes [143]. We areg large-scale meta data processing.
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data in order to enhance biomarker translation, as shown
in Figure 2. We suggest that pancreatic tumor samples are
analyzed with quantitative proteomics and RNA-Seq.
Identification and quantification are performed at the pro-
tein and transcript levels, and a custom protein database is
generated from the RNA-Seq data. Comparisons are made
between protein and transcript data, and the custom pro-
tein database is used to search for proteins. Validated pro-
tein identifications are queried against protein databases
such as Human Protein Atlas [144] and neXtProt [145] to
determine levels of protein evidence, and quantitative
proteomic data are used to generate networks in Ingenuity
Pathway Analysis. Proteins and transcripts are related to
genomic data in ENCODE.
Summary
The characterization of the pancreatic cancer proteome
will inevitably increase our knowledge of pancreatic
tumorigenesis. Many of the hitherto identified proteins
are involved in crucial steps in pancreatic cancer pro-
gression such as cell proliferation, adhesion, migration,
invasion, metastasis, immune response and angiogenesis.
These new protein biomarker candidates will provide es-
sential information for the development of screening
tests and targeted therapies. Quantitative mass spec-
trometry may also be useful in identifying the signaling
that is aberrantly activated in pancreatic cancer [146] or
identifying the metabolites from pancreatic cancer pa-
tients [147]. With the introduction of improved prote-
omic techniques we are thus heading towards a more
personalized medical (PM) approach, with the ability to
provide useful guidance in selecting the right patient for
PM-treatment. The technical development in mass spec-
trometry instrumentation, sample preparation methods,
and protein identification methods is rapidly changing the
way clinical studies measure biomarkers in patient sam-
ples. We can now measure proteins at low abundance
levels and there are a number of studies that have utilized
trace enrichment utilizing antibody probes to reach down
to picogram per milliliter sensitivities [127,128]. A recent
paper by Lopez and colleagues provide data where they
have quantified a large number of proteins utilizing immu-
noaffinity enrichment [148]. In addition to the measure-
ment advancements, commercial dedicated small robotics
is commonly used to handle the multiple step sample
preparations, and as such become a necessary and efficient
step in the work process within clinical studies. It can be
foreseen that sequence based mass spectrometry assays
and platforms that provide multiplex read-out will gain
much attention, and that it will become a milestone in fu-
ture clinical science. The ability to screen patient samples
with panels of hundreds of protein biomarkers with abso-
lute quantitation provides an increased value. The futuregeneration of personalized medicine where the individual
patient will receive the best possible medicine for the cor-
rect disease will drive the entire diagnostics field forward.
Studies such as the NCI Clinical Proteomic Technology
Assessment for Cancer initiative (NCI-CPTAC) that are
publicly available, are examples of milestone achievements
that are changing the everyday routines in clinical sci-
ences. The outline details and information on the initiative
of the national cancer institute can be found at http://pro-
teomics.cancer.gov/programs/cptacnetwork. The new ini-
tiative provides data on applying new technologies for
biomarker verification in plasma [149].
Concluding remarks
In respect to perform deep mining protein sequencing on
pancreatic cancer patients by mass spectrometry, the
Chromosome-Centric Human Proteome Project (C-HPP,
www.c-hpp.org) provides resources that enables novel an-
notations to be verified. The C-HPP consortia aimes at
identifying all proteins encoded by the human chromo-
somes [19]. The link to the ENCODE Consortium, has re-
cently been presented where genomics exon verifications
can be identified on a protein sequence level [150].
The challenge is to couple the gene sequences to rele-
vant amino acid sequences utilizing the ENCODE bio-
informatic engines. This approach was recently presented
in a recent brain tumor study, that can be adapted to pan-
creatic cancer [151].
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